New York, May 30, 2026, 11:05 (EDT)
- Definitive Healthcare ended Friday at $0.93, rising 4.88%. The U.S. trading week was shortened because of the holiday.
- The stock remains under $1, a level important for Nasdaq’s continued-listing rules if the slump lasts.
- Investors look to next week with a small rebound on the table, while revenue is down, goodwill gets a big write-down, and the 2026 outlook from management is in focus.
Definitive Healthcare Corp. finished the holiday-shortened week up, gaining 4.88% Friday to settle at $0.93. The healthcare data company is still trading below the $1 level, which has been a key line for the stock. About 574,000 shares changed hands, with trading in a range from $0.84 to $0.97.
Rebound timing is in focus this week as U.S. markets were closed over the weekend and again on Monday, May 25, for Memorial Day. That gives investors just a few days to figure out if the bounce lasts. Nasdaq notes that normal hours are Monday to Friday, 9:30 a.m. to 4 p.m. ET.
Stocks pushed higher Friday. The S&P 500 added 0.2% to close at another record, while the Dow rose 0.7% and the Nasdaq Composite climbed 0.2%. The Nasdaq advanced 2.4% this week. Small caps missed the rally, with the Russell 2000 off 0.6% on Friday.
Definitive shares have lagged behind the indexes. MarketBeat said the stock is down about 72% for the last year, off around 68% year to date, including Friday’s rebound. Latest closing market cap stood at about $98 million.
Framingham, Massachusetts-based Definitive Healthcare Corp sells data and analytics for the business side of healthcare. The investor page shows the latest news was a May 21 product update. The most recent event listed is the May 7 first-quarter earnings call.
Definitive rolled out a May 21 update to make its data mesh with customer workflows. The company said it grew medical claims coverage, built in a HubSpot integration, gave Salesforce users access to its healthcare professional data and put AI search into some products. “Customers need a complete, connected view of the healthcare market,” chief commercial officer Tina Hannagan said. Definitive Healthcare Corp
Definitive is seeing a harder quarter for earnings. The company posted Q1 revenue of $55.9 million, a 6% drop from the same period last year. Net loss widened to $192.4 million, which included a $197.2 million goodwill impairment tied to an earlier acquisition. CEO Kevin Coop said the quarter landed “at or above the high end” of guidance. SEC
The company is looking for second-quarter revenue of $55 million to $56 million and sees adjusted EBITDA between $13.5 million and $14.5 million. Adjusted EBITDA takes out interest, taxes, depreciation, amortization, and items management says aren’t part of regular business. For 2026, it’s targeting revenue in a range of $220 million to $226 million.
Healthcare software and data stocks moved in different directions Friday. Doximity added 1.5%, Veeva Systems was up 6.0%, but Health Catalyst dropped 0.7%. The split points to Friday’s action in Definitive not being just a sector trade.
Risks are clear enough. Nasdaq’s listing rules call for a minimum $1 bid. If shares trade below that for 30 business days, a deficiency gets triggered. Definitive said falling stock also triggered goodwill reviews. If the price drops toward May’s low around $0.80, listing and liquidity questions will likely get louder, along with concerns over investor confidence.
Definitive shares this week will test buyers’ willingness to chase the price back to $1 and how much support comes from the broader rally going into the May U.S. payrolls data on June 5. The stock has bounced for now. The chart is still damaged.
